Antiviral properties of trans-δ-viniferin derivatives against enveloped viruses.

Broad-spectrum antiviral Influenza virus SARS-CoV-2 Stilbene dimer derivatives Virucidal

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 22 02 2023
revised: 19 04 2023
accepted: 30 04 2023
medline: 29 5 2023
pubmed: 7 5 2023
entrez: 6 5 2023
Statut: ppublish

Résumé

Over the last century, the number of epidemics caused by RNA viruses has increased and the current SARS-CoV-2 pandemic has taught us about the compelling need for ready-to-use broad-spectrum antivirals. In this scenario, natural products stand out as a major historical source of drugs. We analyzed the antiviral effect of 4 stilbene dimers [1 (trans-δ-viniferin); 2 (11',13'-di-O-methyl-trans-δ-viniferin), 3 (11,13-di-O-methyl-trans-δ-viniferin); and 4 (11,13,11',13'-tetra-O-methyl-trans-δ-viniferin)] obtained from plant substrates using chemoenzymatic synthesis against a panel of enveloped viruses. We report that compounds 2 and 3 display a broad-spectrum antiviral activity, being able to effectively inhibit several strains of Influenza Viruses (IV), SARS-CoV-2 Delta and, to some extent, Herpes Simplex Virus 2 (HSV-2). Interestingly, the mechanism of action differs for each virus. We observed both a direct virucidal and a cell-mediated effect against IV, with a high barrier to antiviral resistance; a restricted cell-mediated mechanism of action against SARS-CoV-2 Delta and a direct virustatic activity against HSV-2. Of note, while the effect was lost against IV in tissue culture models of human airway epithelia, the antiviral activity was confirmed in this relevant model for SARS-CoV-2 Delta. Our results suggest that stilbene dimer derivatives are good candidate models for the treatment of enveloped virus infections.

Identifiants

pubmed: 37148860
pii: S0753-3322(23)00615-7
doi: 10.1016/j.biopha.2023.114825
pmc: PMC10158552
pii:
doi:

Substances chimiques

Antiviral Agents 0
delta-viniferin 0
Stilbenes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114825

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Microorganisms. 2021 Jun 01;9(6):
pubmed: 34205874
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Front Plant Sci. 2022 Jan 13;12:805610
pubmed: 35095976
J Virol. 1996 Jun;70(6):4188-92
pubmed: 8648766
Expert Opin Drug Deliv. 2013 Sep;10(9):1287-302
pubmed: 23730924
J Biomol Struct Dyn. 2021 Jun;39(9):3099-3114
pubmed: 32329408
Nat Mater. 2018 Feb;17(2):195-203
pubmed: 29251725
Sci Rep. 2019 Dec 20;9(1):19525
pubmed: 31862939
Crit Care Res Pract. 2010;2010:
pubmed: 20948883
J Nat Prod. 2017 Apr 28;80(4):887-898
pubmed: 28332842
Acta Pharm Sin B. 2016 May;6(3):243-52
pubmed: 27175336
Mar Drugs. 2010 Oct 11;8(10):2619-38
pubmed: 21116410
J Nat Prod. 2020 Aug 28;83(8):2347-2356
pubmed: 32705864
Adv Sci (Weinh). 2020 Dec 14;8(3):2001012
pubmed: 33552848
Front Chem. 2022 Apr 19;10:881298
pubmed: 35518712
Sci Rep. 2021 Jul 12;11(1):14295
pubmed: 34253743
AAPS J. 2021 Jan 5;23(1):14
pubmed: 33400058
J Virol. 2018 May 14;92(11):
pubmed: 29563290
J Virol. 2007 Nov;81(22):12439-49
pubmed: 17855549
Clin Microbiol Rev. 2015 Jul;28(3):603-61
pubmed: 26016486
PLoS Pathog. 2018 Aug 3;14(8):e1007190
pubmed: 30075025
Commun Biol. 2022 Oct 10;5(1):1075
pubmed: 36216966
Sci Rep. 2020 Jul 22;10(1):12523
pubmed: 32694540
Science. 2009 Jul 10;325(5937):161-5
pubmed: 19589993
J Allergy Clin Immunol. 2018 Jun;141(6):2074-2084
pubmed: 28797733
Expert Rev Anti Infect Ther. 2010 Jun;8(6):635-8
pubmed: 20521891
Front Chem. 2022 May 31;10:912396
pubmed: 35711965

Auteurs

Arnaud Charles-Antoine Zwygart (AC)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Chiara Medaglia (C)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Robin Huber (R)

School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU - Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.

Romain Poli (R)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Laurence Marcourt (L)

School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU - Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.

Sylvain Schnee (S)

Agroscope, Plant Protection Research Division, Mycology Group, Route de Duillier 50, P.O. Box 1012, 1260 Nyon, Switzerland.

Emilie Michellod (E)

Agroscope, Plant Protection Research Division, Mycology Group, Route de Duillier 50, P.O. Box 1012, 1260 Nyon, Switzerland.

Beryl Mazel-Sanchez (B)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Samuel Constant (S)

Epithelix Sarl, Chemin des Aulx 18, 1228 Plan-les-Ouates, Switzerland.

Song Huang (S)

Epithelix Sarl, Chemin des Aulx 18, 1228 Plan-les-Ouates, Switzerland.

Meriem Bekliz (M)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Sophie Clément (S)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland.

Katia Gindro (K)

Agroscope, Plant Protection Research Division, Mycology Group, Route de Duillier 50, P.O. Box 1012, 1260 Nyon, Switzerland.

Emerson Ferreira Queiroz (EF)

School of Pharmaceutical Sciences, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU - Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.

Caroline Tapparel (C)

Department of Microbiology and Molecular Medicine, University of Geneva, CMU - Rue Michel-Servet 1, CH-1211 Geneva 4, Switzerland. Electronic address: caroline.tapparel@unige.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH